share_log

四環醫藥：自願公告-惠升生物研發的SGLT-2抑制劑創新藥脯氨酸加格列淨片獲國家藥監局批准上市

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-HUISHENG BIOPHARMACEUTICAL''S SGLT-2 INHIBITOR INNOVATIVE DRUG PROLINE JANAGLIFLOZIN TABLETS OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

香港交易所 ·  Jan 22 17:06
Summary by Moomoo AI
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司研發的SGLT-2抑制劑創新藥——脯氨酸加格列淨片（商品名：惠優靜®），已獲得中國國家藥品監督管理局的上市批准，用於治療2型糖尿病。此創新藥是國內第二個獲批的自主研發SGLT-2抑制劑，顯示出惠升生物在糖尿病治療領域的突破性進展。加格列淨片的臨床III期研究數據表明，其具有顯著的降糖療效和良好的總體安全性。惠升生物擁有該藥物在中國及多個國家和地區的專利權。四環醫藥於2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司研發的SGLT-2抑制劑創新藥——脯氨酸加格列淨片（商品名：惠優靜®），已獲得中國國家藥品監督管理局的上市批准，用於治療2型糖尿病。此創新藥是國內第二個獲批的自主研發SGLT-2抑制劑，顯示出惠升生物在糖尿病治療領域的突破性進展。加格列淨片的臨床III期研究數據表明，其具有顯著的降糖療效和良好的總體安全性。惠升生物擁有該藥物在中國及多個國家和地區的專利權。四環醫藥於2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
Four Ring Pharmaceutical Holdings Group Limited announces that its SGLT-2 inhibitor innovative drug, proline Gagli tablets (trade name: Huijing®), developed by its non-wholly-owned subsidiary, Huichang Biopharmaceuticals Co., Ltd., has been approved for listing by the National Drug Administration of China for the treatment of Type 2 Diabetes. This innovative drug is the second independently developed SGLT-2 inhibitor in the country, demonstrating breakthrough advances in the field of diabetes treatment by Pupil Biome. Data from a Phase III clinical trial of the Gagli tablet show that it has significant hypoglycemic efficacy and good overall safety. Wellcome owns the patent rights to the drug in China and several countries and regions. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
Four Ring Pharmaceutical Holdings Group Limited announces that its SGLT-2 inhibitor innovative drug, proline Gagli tablets (trade name: Huijing®), developed by its non-wholly-owned subsidiary, Huichang Biopharmaceuticals Co., Ltd., has been approved for listing by the National Drug Administration of China for the treatment of Type 2 Diabetes. This innovative drug is the second independently developed SGLT-2 inhibitor in the country, demonstrating breakthrough advances in the field of diabetes treatment by Pupil Biome. Data from a Phase III clinical trial of the Gagli tablet show that it has significant hypoglycemic efficacy and good overall safety. Wellcome owns the patent rights to the drug in China and several countries and regions. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more